Hexarelin
Hexarelin (Examorelin)
Early-stage clinical evidence exists but is limited. Larger, well-controlled trials are needed.
A synthetic peptide that produces the strongest single-dose growth hormone release of any peptide in its class, though it also raises stress hormones (cortisol) and prolactin. It has also shown heart-protective effects in animal studies through a separate mechanism unrelated to growth hormone. This peptide is not FDA-approved.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Across small human studies, hexarelin repeatedly raised ACTH, cortisol, and prolactin alongside GH stimulation (PMID 9430449, PMID 11238504, DOI 10.1007/BF03350297). In the 16-week chronic study, repeated dosing caused partial but reversible reduction in GH responsiveness without significant changes in IGF-1, lean mass, fat mass, or bone mineral density (PMID 9589671). Review material notes shorter stage 4 sleep after hexarelin (PMC5632578 via). Some users report flushing and water retention but these are not systematically documented in clinical studies.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-19]